AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-15. (Cancelled)

16. (New) A method of processing an inhaler component of a dry powder inhaler, the method comprising:

exposing the inhaler component, in a chamber, to a gas at a first pressure of no more than 200 mbar;

exposing the inhaler component, in the chamber, to gas at a second pressure greater than the first pressure; and

repeating the exposure of the inhaler component to gas at a pressure no greater than 200 mbar;

wherein the exposing steps reduce an electrostatic charge of the inhaler component.

17. (New) The method of claim 16, wherein the second pressure is atmospheric pressure.

18. (New) The method of claim 16, wherein the inhaler component is the entire dry powder inhaler.

19. (New) The method of claim 16, comprising twice repeating the exposure of the inhaler component to the gas at the first pressure.

20. (New) The method of claim 16, wherein the gas is air.

21. (New) The method of claim 16, wherein the first pressure is less than 100mbar.

22. (New) The method of claim 16, wherein the first pressure is less than 50mbar.

23. (New) The method of claim 16, wherein the first pressure is less than 1mbar.

24. (New) The method of claim 16, further comprising:

placing the dry powder inhaler or inhaler component in the chamber;

closing the chamber;

reducing the internal pressure of the chamber using a pump; and

using a measuring device to control the pump so as to reduce the pressure in the chamber to the first pressure,

wherein the measuring device automatically controls the pump to repeat the exposure of the inhaler component to the gas at the first pressure.

25. (New) The method of claim 16, wherein the dry powder inhaler or inhaler component contains a dry powder formulation, the formulation comprising one or more

drugs selected from the group consisting of: mometasone, ciclesonide, zoticasone, flumoxonide, fluticasone, budesonide, salmeterol, formoterol, and tiotropium bromide.

26. (New) The method of claim 16, wherein the inhaler component contains a dry powder formulation, the formulation comprising one or more drug combinations selected from the group consisting of: fluticasone propionate/salmeterol xinafoate, ciclesonide/formoterol fumarate dihydrate, mometasone furoate/formoterol fumarate dihydrate, budesonide/formoterol fumarate dihydrate, fluticasone propionate/formoterol fumarate dehydrate, and tiotropium bromide/formoterol fumarate dihydrate.

27. (New) The method of claim 16, wherein the inhaler component contains a dry powder formulation, the formulation comprising one or more drug combinations selected from the group consisting of budesonide and formoterol fumarate dihydrate.

28. (New) The method of claim 25, wherein the mometasone is furoate.

29. (New) The method of claim 26, wherein the fluticasone is 17-propionate.

30. (New) The method of claim 25, wherein the salmeterol is xinafoate.

31. (New) The method of claim 25, wherein the formoterol is fumarate dehydrate.

32. (New) A dry powder inhaler prepared according to the method of claim 16.